Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer’s disease

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

Within the last 5 years, Clive Ballard has received honoraria from Novartis and Eisai Pharmaceutical Companies who have an interest in cholinesterase inhibitor therapies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.